Business
Marina Biotech Acquires Prestalia(R), a U.S. FDA Approved Drug for Patients Whose Blood Pressure Is Not Adequately Controlled by Monotherapy
Marina Biotech Acquires Prestalia(R), a U.S. FDA Approved Drug for Patients Whose Blood Pressure Is Not Adequately Controlled by Monotherapy.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Marina Biotech Acquires Prestalia(R), a U.S. FDA Approved Drug for Patients Whose Blood Pressure Is Not Adequately Controlled by Monotherapy\n \n \nMarina Biotech Acquires Prestalia(R), a U.S. FDA Approved Drug for Patients Whose Blood Pressure Is Not Adequately Controlled by Monotherapy\n\nPrestalia provides an immediate commercial opportunity for Marina\nProduct will be marketed using the patented telehealth technology platform, DyrctAxess(TM)\n\n \n CITY OF INDUSTRY, CA--(Marketwired - Jun 6, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that it has acquired Prestalia®, a treatment of hypertension, from Symplmed Pharmaceuticals Inc. Hypertension remains a significant health issue in the U.S., affecting approximately 34% of adults ages 20 and over, in 2013 to 2014; and approximately 30,200 deaths from essential hypertension and hypertensive renal disease, in 2014, according to the CDC.\n Prestalia will be marketed using Symplmed's patented telehealth technology platform, DyrctAxess™, which enables direct delivery of medications to a patient's home and helps to address the problem of poor compliance resulting from unfilled prescriptions. Prestalia is protected by two patents listed in the U.S. FDA's publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The two Prestalia U.S. patents (6696481 and 7846961) offer the potential for product exclusivity until 2029.\n Joseph Ramelli, CEO of Marina Biotech, stated, \"This is a transformative event for Marina Biotech. In addition to bringing a commercial hypertension product into the Company, we believe there will be longer term benefits for our existing portfolio. For example, our two existing hypertension therapies, IT102 and IT103, if approved by the FDA, will benefit from the distribution capabilities we will have in place for Prestalia. This could provide us with a much faster and cost effective go-to-market strategy for these two therapies.\" \n Dr. Vuong Trieu, Chairman of Marina Biotech, stated, \"With the acquisition of Prestalia, Marina Biotech is poised to become an important player in the field of specialty pharma for...